ES2736283T3 - Procedimientos para aislar hemoderivados a partir de un material hemoderivado empobrecido en proteína interalfainhibidora - Google Patents

Procedimientos para aislar hemoderivados a partir de un material hemoderivado empobrecido en proteína interalfainhibidora Download PDF

Info

Publication number
ES2736283T3
ES2736283T3 ES14740523T ES14740523T ES2736283T3 ES 2736283 T3 ES2736283 T3 ES 2736283T3 ES 14740523 T ES14740523 T ES 14740523T ES 14740523 T ES14740523 T ES 14740523T ES 2736283 T3 ES2736283 T3 ES 2736283T3
Authority
ES
Spain
Prior art keywords
factor
blood
igg
depleted
iaip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14740523T
Other languages
English (en)
Spanish (es)
Inventor
Yow-Pin Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothera Biologics Inc
Original Assignee
Prothera Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51208188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2736283(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prothera Biologics Inc filed Critical Prothera Biologics Inc
Application granted granted Critical
Publication of ES2736283T3 publication Critical patent/ES2736283T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES14740523T 2013-01-18 2014-01-17 Procedimientos para aislar hemoderivados a partir de un material hemoderivado empobrecido en proteína interalfainhibidora Active ES2736283T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754366P 2013-01-18 2013-01-18
PCT/US2014/012033 WO2014113659A1 (en) 2013-01-18 2014-01-17 Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material

Publications (1)

Publication Number Publication Date
ES2736283T3 true ES2736283T3 (es) 2019-12-27

Family

ID=51208188

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14740523T Active ES2736283T3 (es) 2013-01-18 2014-01-17 Procedimientos para aislar hemoderivados a partir de un material hemoderivado empobrecido en proteína interalfainhibidora

Country Status (7)

Country Link
US (2) US20140206844A1 (de)
EP (1) EP2945962B1 (de)
CN (1) CN105209477A (de)
AU (1) AU2014207447B2 (de)
CA (1) CA2921692A1 (de)
ES (1) ES2736283T3 (de)
WO (1) WO2014113659A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (de) 2003-11-08 2016-11-02 Prothera Biologics Zusammensetzung von inter-alpha-hemmer-proteinen aus plasma zur therapeutische verwendung
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
WO2014039987A2 (en) * 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20190269765A1 (en) 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
CN108144586B (zh) * 2016-12-05 2020-07-17 中国水产科学研究院黄海水产研究所 对氨基苯甲脒仿生亲和配基的仿生亲和纯化方法
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CA3173539A1 (en) * 2020-03-31 2021-10-07 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN112028988A (zh) * 2020-10-16 2020-12-04 哈尔滨派斯菲科生物制药股份有限公司 一种冻干型人凝血因子viii的制备方法
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
AT379310B (de) 1983-05-20 1985-12-27 Immuno Ag Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates
EP0317376B2 (de) 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat
GB8729822D0 (en) 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
FR2706466B1 (fr) * 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
JP2004511492A (ja) * 2000-10-13 2004-04-15 オクタファルマ　アクチェン　ゲゼルシャフト ビクニンを含む血漿画分、その調製方法、およびその使用
EP3087991A1 (de) 2003-11-08 2016-11-02 Prothera Biologics Zusammensetzung von inter-alpha-hemmer-proteinen aus plasma zur therapeutische verwendung
EP1765866B1 (de) * 2004-06-07 2014-01-08 Therapure Biopharma Inc. Isolierung von plasma- oder serumprotein
GB0524432D0 (en) 2005-11-30 2006-01-11 Nhs Blood & Transplant Method
CN101274956B (zh) 2008-04-11 2011-10-05 三九集团湛江开发区双林药业有限公司 从人血浆组分FIV沉淀中分离纯化α1-抗胰蛋白酶的方法
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
US9127043B2 (en) 2009-03-05 2015-09-08 Biogen Ma Inc. Purification of immunoglobulins
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
BR112013001753A2 (pt) * 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.

Also Published As

Publication number Publication date
US20140206844A1 (en) 2014-07-24
EP2945962A4 (de) 2016-11-02
AU2014207447B2 (en) 2018-11-15
EP2945962B1 (de) 2019-04-17
CA2921692A1 (en) 2014-07-24
US20150361127A1 (en) 2015-12-17
CN105209477A (zh) 2015-12-30
AU2014207447A1 (en) 2015-09-03
WO2014113659A1 (en) 2014-07-24
HK1217721A1 (en) 2017-01-20
EP2945962A1 (de) 2015-11-25

Similar Documents

Publication Publication Date Title
EP2945962B1 (de) Verfahren zur isolierung von blutprodukten aus einem inter-alpha-inhibitorprotein-abgereicherten blutproduktmaterial
JP7774384B2 (ja) 治療タンパク質の精製方法
JP5713880B2 (ja) フィブリノゲンの精製
AU2007209363B2 (en) Purification and use of a factor for supporting wound healing
RU2663792C2 (ru) Способ очистки фибриногена, продукт фибриногена и средство для очистки или производства продукта фибриногена
AU2003244850B2 (en) Processes for the preparation of fibrinogen
HK1217721B (en) Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
JP7144113B2 (ja) 血液製剤から第ｖｉｉｉ因子を分離する方法
Radosevich et al. Affinity chromatography–fractionated and DNA-engineered plasma proteins
CA2833631C (en) Novel process for the preparation of a virus-inactivated fv concentrate starting from human plasma, scalable to industrial level
RADOSEVICH et al. AFFINITY CHROMATOGRAPHY OF PLASMA PROTEINS
CA3173539A1 (en) A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
MX2008009204A (en) Purification and use of a factor for supporting wound healing